Please check your internet connection and try again.
# Urimax (Tamsulosin)
## Overview
Tamsulosin is a selective α1-adrenoceptor antagonist that preferentially binds to α1A receptors in the prostate and bladder neck, causing smooth muscle relaxation and improved urinary flow.
## Primary Indications
* Treatment of signs and symptoms of Benign Prostatic Hyperplasia (BPH).
* Off-label: Medical expulsive therapy for ureteral calculi.
## Adult Dosing
* **BPH:** 0.4 mg orally once daily, taken 30 minutes after the same meal each day.
* If symptoms do not improve after 2–4 weeks, the dose may be increased to 0.8 mg once daily.
* **Maximum Dose:** 0.8 mg daily.
## Pediatric Dosing
* **Not indicated/established for routine use.** Usage in children for neurogenic bladder or voiding dysfunction is strictly off-label and varies significantly by institution/local protocol; consultation with a pediatric urologist is mandatory.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment indicated for mild-to-moderate impairment. Use with caution in severe renal impairment (CrCl <10 mL/min).
* **Hepatic Impairment:** Not recommended in severe hepatic impairment.
* **CYP3A4/2D6 Inhibitors:** Reduce dose or interrupt therapy if co-administered with strong inhibitors (e.g., ketoconazole).
## Contraindications
* Known hypersensitivity to tamsulosin or any component of the formulation.
## Adverse Effects
* **Common:** Orthostatic hypotension, dizziness, headache, abnormal ejaculation (retrograde ejaculation), rhinitis.
* **Serious:** Syncope (especially post-first dose), priapism, Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery.
## Key Drug Interactions
* **PDE5 Inhibitors:** Concomitant use (e.g., sildenafil, tadalafil) may result in additive blood pressure lowering effects; initiate PDE5 inhibitors at the lowest possible dose.
* **Strong CYP3A4 Inhibitors:** (e.g., clarithromycin, ritonavir, ketoconazole) significantly increase plasma concentrations of tamsulosin.
* **Antihypertensives:** Potential for increased risk of hypotension.
## Monitoring
* Monitor for orthostatic hypotension, particularly upon initiation or dose escalation.
* Assess symptom improvement (e.g., IPSS score) after 2–4 weeks.
* Blood pressure monitoring if clinical symptoms of hypotension occur.
## Clinical Pearls
* **Administration:** Must be swallowed whole; do not crush, chew, or open the capsule to ensure controlled release.
* **Surgical Risk:** Clinicians should screen patients for planned cataract or glaucoma surgery. Tamsulosin may cause IFIS; ophthalmologists should be notified of current or past tamsulosin use.
* **First-Dose Phenomenon:** Advise patients to rise slowly from a sitting or lying position to mitigate dizziness and orthostatic hypotension.
***
**Disclaimer:** This information is for educational purposes and does not replace professional clinical judgment. Prescribers should verify current, site-specific prescribing information, package inserts, and local institutional protocols before administering this medication.
